Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia.

Soran H, Ho JH, Adam S, Durrington PN.

Curr Opin Lipidol. 2019 Aug;30(4):263-272. doi: 10.1097/MOL.0000000000000614.

PMID:
31219837
2.

Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: Small, dense low-density lipoprotein and interleukin-6.

Adam S, Liu Y, Siahmansur T, Ho JH, Dhage SS, Yadav R, New JP, Donn R, Ammori BJ, Syed AA, Malik RA, Soran H, Durrington PN.

Diab Vasc Dis Res. 2019 Mar;16(2):144-152. doi: 10.1177/1479164119826479.

PMID:
31014098
3.

The Reaven syndrome: An historical perspective.

Soran H, Adam S, Ho JH, Durrington PN.

Diab Vasc Dis Res. 2019 Mar;16(2):116-117. doi: 10.1177/1479164119828899. No abstract available.

PMID:
31014096
4.

Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".

Soran H, Adam S, Durrington PN.

Atherosclerosis. 2019 Feb;281:214-215. doi: 10.1016/j.atherosclerosis.2018.11.033. Epub 2018 Nov 28. No abstract available.

PMID:
30528192
5.

Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.

Humphries SE, Cooper JA, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H, Neil AHW; Simon Broome Familial Hyperlipidaemia Register Group.

Atherosclerosis. 2019 Feb;281:207-212. doi: 10.1016/j.atherosclerosis.2018.11.014. Epub 2018 Nov 12.

6.

Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.

Soran H, Adam S, Durrington PN.

Atherosclerosis. 2018 Nov;278:135-142. doi: 10.1016/j.atherosclerosis.2018.08.040. Epub 2018 Aug 30.

PMID:
30273874
7.

Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.

Colombo M, Looker HC, Farran B, Agakov F, Brosnan MJ, Welsh P, Sattar N, Livingstone S, Durrington PN, Betteridge DJ, McKeigue PM, Colhoun HM.

Atherosclerosis. 2018 Jul;274:182-190. doi: 10.1016/j.atherosclerosis.2018.05.014. Epub 2018 May 25.

8.

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Humphries SE, Cooper JA, Seed M, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H, Neil HAW; Simon Broome Familial Hyperlipidaemia Register Group.

Atherosclerosis. 2018 Jul;274:41-46. doi: 10.1016/j.atherosclerosis.2018.04.040. Epub 2018 May 1.

9.

Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets.

Soran H, Ho JH, Durrington PN.

Curr Opin Lipidol. 2018 Aug;29(4):318-326. doi: 10.1097/MOL.0000000000000526. Review.

PMID:
29746303
10.

Hypercholesterolaemia - practical information for non-specialists.

Soran H, Adam S, Mohammad JB, Ho JH, Schofield JD, Kwok S, Siahmansur T, Liu Y, Syed AA, Dhage SS, Stefanutti C, Donn R, Malik RA, Banach M, Durrington PN.

Arch Med Sci. 2018 Jan;14(1):1-21. doi: 10.5114/aoms.2018.72238. Epub 2017 Dec 19.

11.

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.

Soran H, Liu Y, Adam S, Siahmansur T, Ho JH, Schofield JD, Kwok S, Gittins M, France M, Younis N, Gibson JM, Durrington PN, Rutter MK.

J Clin Lipidol. 2018 Jan - Feb;12(1):44-55. doi: 10.1016/j.jacl.2017.10.011. Epub 2017 Nov 13.

PMID:
29246729
12.

Editorial introduction.

Durrington PN.

Curr Opin Lipidol. 2017 Aug;28(4):v. doi: 10.1097/MOL.0000000000000439. No abstract available.

PMID:
28700378
13.

Evidence for more intensive cholesterol lowering.

Soran H, Kwok S, Adam S, Ho JH, Durrington PN.

Curr Opin Lipidol. 2017 Aug;28(4):291-299. doi: 10.1097/MOL.0000000000000433. Review.

PMID:
28509674
14.

Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients.

Durrington PN, Soran H.

Circulation. 2017 Feb 14;135(7):627-629. doi: 10.1161/CIRCULATIONAHA.116.022146. Review. No abstract available.

PMID:
28193795
15.
16.

Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.

Postmus I, Warren HR, Trompet S, Arsenault BJ, Avery CL, Bis JC, Chasman DI, de Keyser CE, Deshmukh HA, Evans DS, Feng Q, Li X, Smit RA, Smith AV, Sun F, Taylor KD, Arnold AM, Barnes MR, Barratt BJ, Betteridge J, Boekholdt SM, Boerwinkle E, Buckley BM, Chen YI, de Craen AJ, Cummings SR, Denny JC, Dubé MP, Durrington PN, Eiriksdottir G, Ford I, Guo X, Harris TB, Heckbert SR, Hofman A, Hovingh GK, Kastelein JJ, Launer LJ, Liu CT, Liu Y, Lumley T, McKeigue PM, Munroe PB, Neil A, Nickerson DA, Nyberg F, O'Brien E, O'Donnell CJ, Post W, Poulter N, Vasan RS, Rice K, Rich SS, Rivadeneira F, Sattar N, Sever P, Shaw-Hawkins S, Shields DC, Slagboom PE, Smith NL, Smith JD, Sotoodehnia N, Stanton A, Stott DJ, Stricker BH, Stürmer T, Uitterlinden AG, Wei WQ, Westendorp RG, Whitsel EA, Wiggins KL, Wilke RA, Ballantyne CM, Colhoun HM, Cupples LA, Franco OH, Gudnason V, Hitman G, Palmer CN, Psaty BM, Ridker PM, Stafford JM, Stein CM, Tardif JC, Caulfield MJ, Jukema JW, Rotter JI, Krauss RM.

J Med Genet. 2016 Dec;53(12):835-845. doi: 10.1136/jmedgenet-2016-103966. Epub 2016 Sep 1.

17.

Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids.

France M, Kwok S, Soran H, Williams S, Ho JH, Adam S, Canoy D, Liu Y, Durrington PN.

Int J Mol Sci. 2016 Jul 8;17(7). pii: E1089. doi: 10.3390/ijms17071089.

18.

Diabetic dyslipidaemia.

Soran H, Schofield JD, Adam S, Durrington PN.

Curr Opin Lipidol. 2016 Aug;27(4):313-22. doi: 10.1097/MOL.0000000000000318. Review.

PMID:
27213628
19.

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS).

Livingstone SJ, Looker HC, Akbar T, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH, Colhoun HM.

Diabetologia. 2016 Feb;59(2):299-306. doi: 10.1007/s00125-015-3802-6. Epub 2015 Nov 17.

20.

Antioxidant properties of HDL.

Soran H, Schofield JD, Durrington PN.

Front Pharmacol. 2015 Oct 16;6:222. doi: 10.3389/fphar.2015.00222. eCollection 2015. Review.

21.

Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.

Soran H, Schofield JD, Durrington PN.

Eur Heart J. 2015 Nov 14;36(43):2975-83. doi: 10.1093/eurheartj/ehv340. Epub 2015 Aug 4.

PMID:
26242714
22.

How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.

Soran H, Schofield JD, Liu Y, Durrington PN.

Curr Opin Lipidol. 2015 Aug;26(4):247-56. doi: 10.1097/MOL.0000000000000194. Review.

PMID:
26103614
23.

Unintended positive and negative effects of drugs on lipoproteins.

Siahmansur TJ, Schofield JD, Azmi S, Liu Y, Durrington PN, Soran H.

Curr Opin Lipidol. 2015 Aug;26(4):325-37. doi: 10.1097/MOL.0000000000000198. Review.

PMID:
26103613
24.

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.

Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, Colhoun HM; CARDS Investigators.

Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22.

25.

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.

Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, Chasman DI, Zhou K, Arsenault BJ, Donnelly LA, Wiggins KL, Avery CL, Griffin P, Feng Q, Taylor KD, Li G, Evans DS, Smith AV, de Keyser CE, Johnson AD, de Craen AJ, Stott DJ, Buckley BM, Ford I, Westendorp RG, Slagboom PE, Sattar N, Munroe PB, Sever P, Poulter N, Stanton A, Shields DC, O'Brien E, Shaw-Hawkins S, Chen YD, Nickerson DA, Smith JD, Dubé MP, Boekholdt SM, Hovingh GK, Kastelein JJ, McKeigue PM, Betteridge J, Neil A, Durrington PN, Doney A, Carr F, Morris A, McCarthy MI, Groop L, Ahlqvist E; Welcome Trust Case Control Consortium, Bis JC, Rice K, Smith NL, Lumley T, Whitsel EA, Stürmer T, Boerwinkle E, Ngwa JS, O'Donnell CJ, Vasan RS, Wei WQ, Wilke RA, Liu CT, Sun F, Guo X, Heckbert SR, Post W, Sotoodehnia N, Arnold AM, Stafford JM, Ding J, Herrington DM, Kritchevsky SB, Eiriksdottir G, Launer LJ, Harris TB, Chu AY, Giulianini F, MacFadyen JG, Barratt BJ, Nyberg F, Stricker BH, Uitterlinden AG, Hofman A, Rivadeneira F, Emilsson V, Franco OH, Ridker PM, Gudnason V, Liu Y, Denny JC, Ballantyne CM, Rotter JI, Adrienne Cupples L, Psaty BM, Palmer CN, Tardif JC, Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J, Caulfield MJ.

Nat Commun. 2014 Oct 28;5:5068. doi: 10.1038/ncomms6068.

26.

With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.

Durrington PN.

Evid Based Med. 2015 Feb;20(1):12. doi: 10.1136/ebmed-2014-110084. Epub 2014 Sep 23. No abstract available.

PMID:
25249694
27.

The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy.

Soran H, Schofield JD, Durrington PN.

Curr Opin Lipidol. 2014 Aug;25(4):239-46. doi: 10.1097/MOL.0000000000000097. Review.

PMID:
24978144
28.

Lipoprotein (a): gene genie.

Durrington PN, Schofield JD, Siahmansur T, Soran H.

Curr Opin Lipidol. 2014 Aug;25(4):289-96. doi: 10.1097/MOL.0000000000000096. Review.

PMID:
24977982
29.

LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.

Hawa MI, Buchan AP, Ola T, Wun CC, DeMicco DA, Bao W, Betteridge DJ, Durrington PN, Fuller JH, Neil HA, Colhoun H, Leslie RD, Hitman GA.

Diabetes Care. 2014 Jun;37(6):1643-9. doi: 10.2337/dc13-2383. Epub 2014 Apr 10.

PMID:
24722498
30.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

31.

Body fat distribution in relation to smoking and exogenous hormones in British women.

Kwok S, Canoy D, Soran H, Ashton DW, Lowe GD, Wood D, Humphries SE, Durrington PN.

Clin Endocrinol (Oxf). 2012 Dec;77(6):828-33. doi: 10.1111/j.1365-2265.2012.04331.x.

PMID:
23137104
32.

Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes.

Younis NN, Soran H, Pemberton P, Charlton-Menys V, Elseweidy MM, Durrington PN.

Clin Sci (Lond). 2013 Mar;124(5):343-9. doi: 10.1042/CS20120304.

PMID:
22985435
33.

High-density lipoprotein impedes glycation of low-density lipoprotein.

Younis NN, Soran H, Charlton-Menys V, Sharma R, Hama S, Pemberton P, Elseweidy MM, Durrington PN.

Diab Vasc Dis Res. 2013 Mar;10(2):152-60. doi: 10.1177/1479164112454309. Epub 2012 Aug 13.

PMID:
22890407
34.

HDL functionality.

Soran H, Hama S, Yadav R, Durrington PN.

Curr Opin Lipidol. 2012 Aug;23(4):353-66. doi: 10.1097/MOL.0b013e328355ca25. Review.

PMID:
22732521
35.

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).

Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, Demicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA; CARDS, ASCOT, and PROSPER Investigators.

J Lipid Res. 2012 May;53(5):1000-11. doi: 10.1194/jlr.P021113. Epub 2012 Feb 24.

36.

Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study.

Seed M, Betteridge DJ, Cooper J, Caslake M, Durrington PN, Thompson GR, Sattar N, Humphries SE, Neil HA.

JRSM Cardiovasc Dis. 2012 Jun 30;1(3). pii: cvd.2012.012011. doi: 10.1258/cvd.2012.012011. eCollection 2012.

37.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.

Soran H, France MW, Kwok S, Dissanayake S, Charlton-Menys V, Younis NN, Durrington PN.

Ann Clin Biochem. 2011 Nov;48(Pt 6):566-71. doi: 10.1258/acb.2011.010277. Epub 2011 Oct 17.

PMID:
22006975
38.

Susceptibility of LDL and its subfractions to glycation.

Soran H, Durrington PN.

Curr Opin Lipidol. 2011 Aug;22(4):254-61. doi: 10.1097/MOL.0b013e328348a43f. Review.

PMID:
21734572
39.

Adiponectin and lipid profiles compared with insulins in relation to early growth of British South Asian and European children: the Manchester children's growth and vascular health study.

Bansal N, Anderson SG, Vyas A, Gemmell I, Charlton-Menys V, Oldroyd J, Pemberton P, Durrington PN, Clayton PE, Cruickshank JK.

J Clin Endocrinol Metab. 2011 Aug;96(8):2567-74. doi: 10.1210/jc.2011-0046. Epub 2011 Jun 1.

40.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.

Eur J Prev Cardiol. 2012 Jun;19(3):474-83. doi: 10.1177/1741826711406616. Epub 2011 Apr 1.

PMID:
21460076
41.

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).

Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK, Durrington PN.

Diabet Med. 2011 Jan;28(1):100-8. doi: 10.1111/j.1464-5491.2010.03139.x.

PMID:
21166851
42.

Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes.

Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, Durrington PN.

Diab Vasc Dis Res. 2010 Oct;7(4):289-95. doi: 10.1177/1479164110383063. Epub 2010 Sep 27.

PMID:
20876207
43.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AF, Imholz BP, Durrington PN, Trip MD, Eriksson M, Visseren FL, Schaefer JR, Kastelein JJ; Triple Study Group.

Clin Ther. 2010 Apr;32(4):615-25. doi: 10.1016/j.clinthera.2010.04.014.

PMID:
20435231
44.

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.

Neil HA, Cooper J, Betteridge DJ, Capps N, McDowell IF, Durrington PN, Seed M, Mann JI, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group.

Atherosclerosis. 2010 Aug;211(2):618-23. doi: 10.1016/j.atherosclerosis.2010.03.006. Epub 2010 Mar 9.

PMID:
20356595
45.

Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations.

Patel JV, Caslake MJ, Vyas A, Cruickshank JK, Prabhakaran D, Bhatnagar D, Reddy KS, Lip GY, Mackness MI, Hughes EA, Durrington PN.

Atherosclerosis. 2010 Apr;209(2):579-84. doi: 10.1016/j.atherosclerosis.2009.10.010. Epub 2009 Oct 13.

PMID:
19922937
46.

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.

Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP.

J Am Coll Cardiol. 2009 Nov 3;54(19):1787-94. doi: 10.1016/j.jacc.2009.06.036.

47.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators.

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
48.

The first recorded heterozygote for familial hypercholesterolemia.

Durrington PN.

J Clin Lipidol. 2009 Apr;3(2):146-8. doi: 10.1016/j.jacl.2009.02.002. Epub 2009 Feb 11. No abstract available.

PMID:
21291805
49.

Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women's Heart Study (UKWHS).

Kwok S, Canoy D, Ashton WD, Lowe GD, Wood D, Humphries SE, Charlton-Menys V, Durrington PN.

Clin Endocrinol (Oxf). 2009 Nov;71(5):727-32. doi: 10.1111/j.1365-2265.2009.03580.x. Epub 2009 Mar 6.

PMID:
19320647
50.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN.

Clin Chem. 2009 Mar;55(3):473-80. doi: 10.1373/clinchem.2008.111401. Epub 2009 Jan 15.

Supplemental Content

Loading ...
Support Center